Bromhexine-d3 (hydrochloride)

Bromhexine-d3 (hydrochloride) is deuterium labeled Bromhexine (hydrochloride) . Bromhexine hydrochloride is a potent and specific TMPRSS2 protease inhibitor with an IC50 of 0.75 μM. Bromhexine hydrochloride can prevent and manage SARS-CoV-2 infection. Bromhexine hydrochloride is an autophagy agonist. Bromhexine hydrochloride is a mucolytic cough suppressant and has the potential for a range of respiratory conditions[1][2][3][4].

Product Specifications

UNSPSC

12352005

Target

Autophagy; HIV; Isotope-Labeled Compounds; SARS-CoV

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Autophagy; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Purity

99.0

Solubility

10 mM in DMSO|DMSO : 20mg/mL (ultrasonic) |H2O : 3.33mg/mL (ultrasonic)

Smiles

BrC1=CC(Br)=C(N)C(CN(C2CCCCC2)C([2H])([2H])[2H])=C1.Cl

Molecular Formula

C14H18D3Br2ClN2

Molecular Weight

415.61

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Jared M Lucas, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014 Nov;4 (11) :1310-25.|[3]Li Wen Shen, et al. TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie. 2017 Nov;142:1-10.|[4]Roberto Maggio, et al. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection. Pharmacol Res. 2020 Jul;157:104837.|[5]Santosh Chauhan, et al. Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential. Nat Commun. 2015 Oct 27;6:8620.